SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

SARS-CoV Related Products (872)
Recombinant Proteins (183)

By Effects:	Controls (5) Inhibitors (789) Degraders (2) Modulators (2) Chemical (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-132306

CCF0058981	Inhibitor	98.02%
CCF0058981 (CCF981), 3-chlorophenyl analogue, is a noncovalent SARS-CoV-2 3CL^pro (SC2) inhibitor with an IC₅₀ of 68 nM. CCF0058981 inhibits SC1 (SARS-CoV-1 3CL^pro) with an IC₅₀ of 19 nM. CCF0058981 has antiviral efficacy and has the potential for COVID-19 research.

HY-124564

Methisazone	Inhibitor	98.26%
Methisazone (Marboran) is an antiviral agent that works by inhibiting mRNA and protein synthesis. Methisazone is also a SARS-CoV-2 (COVID-19) inhibitor. Methisazone is mainly used in pox viruses.

HY-113225S5

Guanosine triphosphate-¹³C₁₀ dilithium
Guanosine triphosphate-¹³C₁₀ (GTP-¹³C₁₀) dilithium is ¹³C-labeled Guanosine triphosphate (HY-113225). Guanosine triphosphate is a native nucleotide. The derivatives of GTP may be used as specific inhibitors against COVID-19.

HY-149606

TKB245	Inhibitor	98.98%
TKB245 is a highly potent SARS-CoV-2 Mpro inhibitor that effectively blocks SARS-CoV-2 replication in VeroE6 cells.

HY-101046

Azaperone dimaleate	Inhibitor	99.87%
Quipazine dimaleate is a 5-HT agonist with a K_i value of 1.4 nM for displaces [3H]GR65630 from 5-HT3R in rat. Quipazine dimaleate shows antiviral activity against SARS-CoV-2 with an EC₅₀ of 31.64 μM. Quipazine dimaleate behaves as a 5-HT3R antagonist in peripheral models. Quipazine dimaleate can be used for neurological disease research.

HY-141622

SDZ 224-015	Inhibitor
SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1. SDZ 224-015 possesses anti-COVID-19 activity, targeting M^pro (IC₅₀ of 30 nM).

HY-108044

ONO-5334	Inhibitor	99.83%
ONO-5334 is a potent, selective and orally active cathepsin K inhibitor with K_i values of 0.10 nM, 0.049 nM and 0.85 nM for human, rabbit and rat cathepsin K, respectively. ONO 5334 is an effective antiviral compound against SAR-COV-2 virus activity with an EC₅₀ value of 500 nM. ONO-5334 has the potential for the study of osteoporosis and COVID-19 disease.

HY-137954

GRL-0496	Inhibitor	99.20%
GRL-0496 is a potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitor, with an IC₅₀ of 30 nM in both enzyme inhibitory and antiviral assays. GRL-0496 shows SARS-CoV antiviral activity, with an EC₅₀ of 6.9 μM.

HY-112163A

rel-Zotatifin	Inhibitor
rel-Zotatifin is the racemic isomer of Zotatifin, acts as an eIF4A inhibitor with activity less than Zotatifin. Zotatifin (eFT226) is a potent, selective, and well-tolerated eIF4A inhibitor. Zotatifin promotes eIF4A binding to specific mRNA sequences with recognition motifs in the 5’-UTRs (IC₅₀=2 nM) and interferes with the assembly of the eIF4F initiation complex.

HY-P99346

Regdanvimab	Inhibitor
Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19.

HY-10574A

Rilpivirine hydrochloride	Inhibitor	99.81%
Rilpivirine (R278474) hydrochloride is a potent and specific diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI). Rilpivirine hydrochloride has high antiviral activity against wild-type HIV (EC₅₀=0.4 nM) and mutant viruses (EC₅₀=0.1-2.0 nM). Rilpivirine hydrochloride has a high genetic barrier to resistance development of HIV.

HY-P99435

Amubarvimab	Inhibitor
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a K_D of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants.

HY-150784

XR8-89	Inhibitor
XR8-89 is a potent papain-like protease (PL^pro) inhibitor with an IC₅₀ value of 0.1 μM. XR8-89 induces conformational changes in SARS-COV-2 papain-like protease, inhibiting SARS-CoV-2 replication. XR8-89 can be used for SARS-CoV-2 research.

HY-153083

COVID-19 Spike Protein mRNA(N1-Me-Pseudo UTP)
COVID-19 Spike Protein mRNA will express COVID-19 spike protein, and suitable for detection of RNA delivery, translation efficiency, cell viability, etc. COVID-19 spike protein is the novel coronavirus pneumonia spike protein located on the membrane surface. COVID-19 spike protein undertakes the functions of virus binding to host cell membrane receptors and membrane fusion, thereby mediating the entry of COVID-19 virus into cells. COVID-19 spike protein is an important site of action for host neutralizing antibodies and a key target for vaccine design.

HY-151482

SARS-CoV-2 Mpro-IN-2	Inhibitor	98.96%
SARS-CoV-2 Mpro-IN-2 (compound GC-14) is a selective, low cytotoxic and non-covalent M^pro inhibitor (IC₅₀=0.40 μM) with good anti-SARS-CoV-2 activity (EC₅₀=1.1 μM). SARS-CoV-2 Mpro-IN-2 can be used in COVID-19 studies.

HY-16762

Artefenomel	Inhibitor	99.14%
Artefenomel (OZ439) is an orally active, synthetic anti-malarial compound containing an artemisinin pharmacophore with a mechanism of action similar to that of artemisinin. Artefenomel has antiviral activity against SARS-CoV-2.

HY-P99889

Romlusevimab	Inhibitor
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

HY-19727A

FOY 251	Inhibitor	98.86%
FOY 251, an anti-proteolytic active metabolite Camostate (HY-13512), acts as a proteinase inhibitor. FOY 251 inhibits SARS-CoV-2 infection in cells assay.

HY-D1270

Direct Violet 1	Inhibitor
Direct Violet 1, an azo dye, is a textile dye. Direct Violet 1 is also the protein-protein interaction (PPI) between the SARS-CoV-2 spike protein and ACE2 inhibitor with IC₅₀s of 1.47-2.63 μM.

HY-17589AS

Chloroquine-d₅	Inhibitor	99.90%
Chloroquine-d₅ is deuterium labeled Chloroquine (HY-17589A). Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC₅₀=1.13 μM).

Name
Email *

	Sorry, but the email address you supplied was invalid.

SARS-CoV

SARS-CoV

SARS-CoV Related Products (872)

Recombinant Proteins (183)

SARS-CoV Related Products (872):